Expression and prognostic significance of microRNA-451 in human epithelial ovarian cancer

Objective: MicroRNA-451 has been proved to be downregulated in many human malignancies and correlated with tumor progression. However, its expression and clinical significance in epithelial ovarian cancer (EOC) is still unclear. The aim of this study was to explore the effects of miR-451 in EOC tumorigenesis and development. Materials and Methods: The expression levels of miR-451 were quantified by qRT-PCR in 115 EOC and 34 normal ovarian tissues, and correlated with clinicopathological factors and prognosis. MTT, flow cytometric assay, and transwell invasion assay were used to test the proliferation, apoptosis, and invasion of SKOV-3 EOC cells transfected with miR-451 mimics or negative control (NC) RNA-oligonucleotides. Results: MiR-451 expression was significantly downregulated in EOC compared with normal ovarian tissues. Low level of miR-451 was associated with advanced FIGO stage (p = 0.005), higher serum CA125 expression level (p = 0.005), and lymph node metastasis (p = 0.002). Multivariate Cox regression analysis identified decreased miR-451 expression as an independent factor predicting poor prognosis for EOC patients. In addition, transfection of miR-451 mimics in SKOV-3 was able to reduce cell proliferation, promote cell apoptosis, and inhibit cell invasion. Conclusions: miR- 451 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of EOC.

MicroRNA-451; Epithelial ovarian cancer; Prognosis; Proliferation; Apoptosis; Invasion.

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2012”. CA Cancer J. Clin., 2012, 62, 10.

[2] Katso R.M., Manek S., Ganjavi H., Biddolph S., Charnock M.F., Bradburn M., et al.: “Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression”. Clin. Cancer Res., 2000, 6, 3271.

[3] Sheng Q., Zhang Y., Wang R., Zhang J., Chen B., Wang J., et al.: “Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer”. Med. Oncol., 2012, 29, 1265.

[4] Paek J., Lee S. H., Yim G.W., Lee M., Kim Y.J., Nam E.J., et al.: “Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 158, 338.

[5] Chen Y., Zhang L.; Hao Q.: “Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation”. Cancer Cell. Int., 2013, 13, 86.

[6] Eckhoff K., Flurschutz R., Trillsch F., Mahner S., Janicke F.; Milde- Langosch K.: “The prognostic significance of Jun transcription factors in ovarian cancer”. J. Cancer Res. Clin. Oncol., 2013, 139, 1673.

[7] Wei W., Mok S.C., Oliva E., Kim S.H., Mohapatra G.; Birrer M.J.: “FGF18 as a prognostic and therapeutic biomarker in ovarian cancer”. J. Clin. Invest., 2013, 123, 4435.

[8] Osman A.: “MicroRNAs in health and disease—basic science and clinical applications”. Clin. Lab., 2012, 58, 393.

[9] Zhao G., Cai C., Yang T., Qiu X., Liao B., Li W., et al: “MicroRNA- 221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma”. PLoS One, 2013, 8, e53906.

[10] Mendell J.T.; Olson E.N.: “MicroRNAs in stress signaling and human disease”. Cell, 2012, 148, 1172.

[11] Dieckmann K. P., Spiekermann M., Balks T., Flor I., Loning T., Bullerdiek J., et al.: “MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours”. Br. J. Cancer, 2012, 107, 1754.

[12] Takahashi M., Cuatrecasas M., Balaguer F., Hur K., Toiyama Y., Castells A., et al.: “The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer”. PLoS One, 2012, 7, e46684.

[13] Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al.: “MicroRNA expression profiles in serous ovarian carcinoma”. Clin. Cancer Res, 2008, 14, 2690.

[14] Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al.: “Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients”. Gynecol. Oncol., 2009, 114, 253.

[15] Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., et al.: “Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer”. Proc. Natl. Acad. Sci. U S A, 2008, 105, 7004.

[16] Peng D.X., Luo M., Qiu L.W., He Y.L.; Wang X.F.: “Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer”. Oncol. Rep., 2012, 27, 1238.

[17] Hu X., Macdonald D.M., Huettner P.C., Feng Z., El Naqa I.M., Schwarz J.K., et al.: “A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer”. Gynecol. Oncol., 2009, 114, 457.

[18] Bandres E., Bitarte N., Arias F., Agorreta J., Fortes P., Agirre X., et al.: “microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells”. Clin. Cancer Res., 2009, 15, 2281.

[19] Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., et al.: “Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin”. Mol. Cancer Ther., 2008, 7, 2152.

[20] Wang R., Wang Z.X., Yang J.S., Pan X., De W.; Chen L.B.: “MicroRNA- 451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14)”. Oncogene, 2011, 30, 2644.

[21] Tian Y., Nan Y., Han L., Zhang A., Wang G., Jia Z., et al.: “MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma”. Int. J.Oncol., 2012, 40, 1105.

[22] Hui AB., Lenarduzzi M., Krushel T., Waldron L., Pintilie M., Shi W., et al.: “Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas”. Clin. Cancer Res., 2010, 16, 1129.

[23] Bian H.B., Pan X., Yang J.S., Wang Z.X.; De W.: “Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549)”. J. Exp. Clin. Cancer Res., 2011, 30, 20.

[24] Zhang T., Liu M., Wang C., Lin C., Sun Y.; Jin D.: “Down-regulationof MiR- 206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression”. Anticancer Res., 2011, 31, 3859.

[25] Wang X.C., Tian L.L., Jiang X.Y., Wang Y.Y., Li D. G., She Y., et al.: “The expression and function of miRNA-451 in non-small cell lung cancer” Cancer Lett., 2011, 311, 203.

[26] Brennecke J., Stark A., Russell R. B.; Cohen S. M.: “Principles of microRNA-target recognition”. PLoS Biol., 2005, 3, e85.

[27] Krek A., Grun D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., et al.: “Combinatorial microRNA target predictions”. Nat. Genet., 2005, 37, 495.